Thomson Reuters (TRI, TRI.TO) announced that it has acquired GeneGo for undisclosed financial terms. Thomson Reuters said that GeneGo will become part of the Healthcare & Science business of Thomson Reuters, effective immediately.
Thomson Reuters said that this acquisition enables it to provide pharmaceutical, biotechnology and academic research communities with solutions that provide better understanding of underlying mechanism of disease and potential therapies.
GeneGo is a provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development. GeneGo is headquartered in San Diego and has offices in Moscow and Michigan.
For comments and feedback: editorial@rttnews.com